financetom
Business
financetom
/
Business
/
EV maker Polestar posts wider quarterly loss on tariffs, pricing pressure
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
EV maker Polestar posts wider quarterly loss on tariffs, pricing pressure
Sep 3, 2025 4:23 AM

STOCKHOLM (Reuters) -Electric vehicle maker Polestar reported a wider loss for the second quarter on Wednesday, after U.S. tariffs and intensifying price pressure led to an impairment charge of its flagship model, Polestar 3.

Despite strong sales in its home market of Europe, demand for Polestar's vehicles was pressured in the U.S., a key region, as a high cost of living and worries of a possible recession prompted consumers to withhold spending on pricey electric cars.

The imposition of U.S. trade tariffs on global trading partners has hit the automotive industry hard, with automakers including Polestar scrambling to adjust supply chains and shift manufacturing to mitigate the impact.

Polestar reported a net loss of $1.03 billion for the quarter ended June 30, compared with a loss of $268 million a year earlier.

The company slashed the recoverable value of the Polestar 3 to $25 million, leading to a $739 million impairment charge recorded in cost of sales.

Polestar has implemented discounts and offers on its vehicles in Europe to lure wary buyers as the continent faces uncertainty due to trade tensions with the U.S.

Offers and discounts have not helped the company in the U.S., which saw a 56% fall in second-quarter sales, as consumers opted for cheaper hybrid and gasoline-powered vehicles over pricey electric ones.

Other U.S. EV makers including Tesla and Rivian also saw declines in second-quarter deliveries.

Polestar's cash position was $719 million at the end of the second quarter, compared with cash of $732 million in the preceding three months.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Iran lifts ban on WhatsApp and Google Play, state media says
Iran lifts ban on WhatsApp and Google Play, state media says
Dec 24, 2024
DUBAI, Dec 24 (Reuters) - Iranian authorities have lifted a ban on Meta's instant messaging platform WhatsApp and Google Play as a first step to scale back internet restrictions, Iranian state media reported on Tuesday. The Islamic Republic has some of the strictest controls on Internet access in the world, but its blocks on U.S.-based social media such as Facebook,...
Mexico's oil and gas output drops to lowest level all year in November
Mexico's oil and gas output drops to lowest level all year in November
Dec 24, 2024
MEXICO CITY, Dec 24 (Reuters) - Mexico's production of liquid hydrocarbon and natural gas in November fell to the lowest levels recorded all year and was well below last year's averages, official numbers published by the regulator showed. November was also the second month the country missed the 1.8 million barrel-per-day production target for crude oil and condensate, which President...
Retail investors buy Novo dip after disappointing weight-loss drug data
Retail investors buy Novo dip after disappointing weight-loss drug data
Dec 24, 2024
By Bhanvi Satija Dec 24 (Reuters) - U.S. retail investor fund flows into Novo Nordisk surged 32-fold on Friday, as the Danish drugmaker's weaker-than-expected obesity drug data offered a rare dip-buying opportunity, according to Vanda Research. Daily net flows climbed to $15.6 million from $0.49 million a day earlier, after eagerly anticipated data showed Novo's experimental drug, CagriSema, helped patients...
Retail investors buy Novo dip after disappointing weight-loss drug data
Retail investors buy Novo dip after disappointing weight-loss drug data
Dec 24, 2024
By Bhanvi Satija (Reuters) - U.S. retail investor fund flows into Novo Nordisk surged 32-fold on Friday, as the Danish drugmaker's weaker-than-expected obesity drug data offered a rare dip-buying opportunity, according to Vanda Research. Daily net flows climbed to $15.6 million from $0.49 million a day earlier, after eagerly anticipated data showed Novo's experimental drug, CagriSema, helped patients cut 22.7%...
Copyright 2023-2026 - www.financetom.com All Rights Reserved